High levels of OCT4expression have been associated with poor prognosis and lower survival rates in patientswith GBM and glioma, likely due to the role of OCT4 in activating the NF-κB/PI3K/AKTpathways and the downstream interregulation of target gene products such as SOX2 and BMI1[ 84– 86]. Here, SOX2 is linked to central nervous system cancer.